Live Breaking News & Updates on Amyloid Diseases

Stay updated with breaking news from Amyloid diseases. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting -February 21, 2024 at 08:02 am EST

- Oral presentation to explore drug effect of sabirnetug on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind assay. ....

United States , Erika Cline , Daniel Oconnell , Jessica Laub , Alex Braun , International Nonproprietary Names , Exchange Commission , Acumen Pharmaceuticals , International Conference On Alzheimer , Drug Administration , Drug Development , Acumen Pharmaceuticals Inc , United States Adopted Name , International Conference , Danielo Connell , Chief Executive Officer , Bioanalytical Methods , Therapeutic Interventions , Amyloid Diseases , Clinical Trials , Fast Track , Private Securities Litigation Reform Act , Annual Report ,